Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug trial aims to tame rare neurological disease Flare-Ups

NCT ID NCT05063162

Ongoing Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

Summary

This study is testing an investigational drug called rozanolixizumab to see if it can prevent relapses and control symptoms in adults with MOG antibody-associated disease (MOG-AD), a rare neurological condition. The trial will involve about 104 participants who will receive either the drug or a placebo to compare effectiveness and safety. The main goal is to see if the drug can delay or prevent disease flare-ups and improve patients' quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOG-AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Mog001 20032

    Suita, Japan

  • Mog001 20049

    Kitakyushu, Japan

  • Mog001 20068

    Chiba, Japan

  • Mog001 20070

    Shinjuku-ku, Japan

  • Mog001 20080

    Taichung, Taiwan

  • Mog001 20094

    Tainan, Taiwan

  • Mog001 20143

    Kodaira, Japan

  • Mog001 20223

    Kōriyama, Japan

  • Mog001 20224

    Sendai, Japan

  • Mog001 20225

    Bunkyō City, Japan

  • Mog001 20226

    Goyang-si, South Korea

  • Mog001 20227

    Sendai, Japan

  • Mog001 20228

    Ternopil, Ukraine

  • Mog001 20307

    Isehara, Japan

  • Mog001 20319

    Kyiv, Ukraine

  • Mog001 30022

    Melbourne, Australia

  • Mog001 40049

    Seville, Spain

  • Mog001 40100

    Madrid, Spain

  • Mog001 40122

    Edegem, Belgium

  • Mog001 40123

    Anderlecht, Belgium

  • Mog001 40124

    Prague, Czechia

  • Mog001 40140

    Göttingen, Germany

  • Mog001 40146

    Pavia, Italy

  • Mog001 40161

    Madrid, Spain

  • Mog001 40163

    Oxford, United Kingdom

  • Mog001 40170

    Strasbourg, France

  • Mog001 40177

    Münster, Germany

  • Mog001 40185

    Ghent, Belgium

  • Mog001 40195

    Hradec Králové, Czechia

  • Mog001 40267

    Barcelona, Spain

  • Mog001 40337

    Bern, Switzerland

  • Mog001 40341

    Málaga, Spain

  • Mog001 40350

    Murcia, Spain

  • Mog001 40386

    Cologne, Germany

  • Mog001 40485

    Coimbra, Portugal

  • Mog001 40550

    Istanbul, Turkey (Türkiye)

  • Mog001 40577

    Ulm, Germany

  • Mog001 40629

    Roma, Italy

  • Mog001 40630

    Zurich, Switzerland

  • Mog001 40646

    Verona, Italy

  • Mog001 40648

    Samsun, Turkey (Türkiye)

  • Mog001 40657

    Bron, France

  • Mog001 40659

    Berlin, Germany

  • Mog001 40661

    Liverpool, United Kingdom

  • Mog001 40663

    Huddinge, Sweden

  • Mog001 40669

    Porto, Portugal

  • Mog001 40721

    Teplice, Czechia

  • Mog001 40723

    Basel, Switzerland

  • Mog001 40725

    Sancaktepe, Turkey (Türkiye)

  • Mog001 40726

    Izmir, Turkey (Türkiye)

  • Mog001 40755

    Montpellier, France

  • Mog001 40756

    Bruxelles/brussel, Belgium

  • Mog001 40840

    Bydgoszcz, Poland

  • Mog001 40849

    Bursa, Turkey (Türkiye)

  • Mog001 40850

    Athens, Greece

  • Mog001 40851

    Thessaloniki, Greece

  • Mog001 50074

    Kansas City, Kansas, 66160, United States

  • Mog001 50101

    Aurora, Colorado, 80045, United States

  • Mog001 50104

    Rochester, Minnesota, 55905, United States

  • Mog001 50243

    Boston, Massachusetts, 02114-3117, United States

  • Mog001 50297

    Scottsdale, Arizona, 85259-5452, United States

  • Mog001 50304

    Dallas, Texas, 75390-9036, United States

  • Mog001 50308

    Tampa, Florida, 33612, United States

  • Mog001 50450

    Palo Alto, California, 94304, United States

  • Mog001 50472

    Peoria, Illinois, 61637, United States

  • Mog001 50473

    Salt Lake City, Utah, 84108, United States

  • Mog001 50485

    Mexico City, Mexico

  • Mog001 50486

    Culiacán, Mexico

  • Mog001 50552

    Baltimore, Maryland, 21287, United States

  • Mog001 50553

    Washington D.C., District of Columbia, 20057, United States

  • Mog001 50568

    San Antonio, Texas, 78229, United States

  • Mog001 50571

    Cleveland, Ohio, 44106, United States

  • Mog001 60033

    Porto Alegre, Brazil

Conditions

Explore the condition pages connected to this study.

MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOG-AD)